We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Sanofi | NASDAQ:SNY | NASDAQ | Depository Receipt |
Price Change | % Change | Price | Bid Price | Offer Price | |
---|---|---|---|---|---|
-0.07 | -0.14% | 48.28 | 48.12 | 48.63 |
High Price | Low Price | Open Price | Traded | Last Trade |
---|---|---|---|---|
48.64 | 47.885 | 48.57 | 3,035,899 | 23:55:41 |
Date | Time | Source | Headline |
---|---|---|---|
23/1/2024 | 11:05 | DJN | Sanofi to Buy Assets From Inhibrx in Deal Valued at Up to $2.2 Billion --.. |
09/1/2024 | 07:14 | DJN | Sanofi Names Brian Foard Head of Specialty-Care Unit |
21/12/2023 | 07:25 | DJN | Sanofi Ends Drug Program After Late-Stage Trial in Lung Cancer Fails |
19/12/2023 | 12:28 | DJN | Innate Pharma Shares Rise after Sanofi Exercises Licensing Option |
11/12/2023 | 22:18 | DJN | Sanofi Terminates Agreement with Maze Therapeutics Following FTC Opposition |
11/12/2023 | 06:50 | DJN | Sanofi Sees Improvement in Trial Results of Cancer Drug Sarclisa |
07/12/2023 | 07:34 | DJN | Sanofi Myeloma Drug Sarclisa Met Primary Goal in Late-Stage Trial |
07/12/2023 | 07:20 | DJN | Sanofi Sees Annual Sales From New Pharma Assets Above $10.8 Billion by 2030 |
06/12/2023 | 13:20 | DJN | Trending: Merck's Multiple Sclerosis Drug Misses Expectations in Late-Stage.. |
06/12/2023 | 10:14 | DJN | Merck Shares Slump After Multiple Sclerosis Drug Fails in Late-Stage Trials |
1 Year Sanofi Chart |
Intraday Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions